
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
Bochum, Germany - Results of a study conducted by researchers at Ruhr University here suggest that an anti-inflammatory drug may help in treating intertriginous psoriasis.